Algorae Pharmaceuticals Ltd Asset Resilience Ratio

Latest as of December 2025: 37.48%

Algorae Pharmaceuticals Ltd asset resilience ratio. Algorae Pharmaceuticals Ltd (1AI) has an Asset Resilience Ratio of 37.48% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 1AI defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$750.00K
≈ $530.67K USD Cash + Short-term Investments

Total Assets

AU$2.00 Million
≈ $1.42 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Algorae Pharmaceuticals Ltd (2016–2025)

Asset resilience ratio of Algorae Pharmaceuticals Ltd from 2016 to 2025. This chart shows how Algorae Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Algorae Pharmaceuticals Ltd for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Algorae Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 1AI total asset value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$750.00K 37.48%
Total Liquid Assets AU$750.00K 37.48%

Asset Resilience Insights

  • Very High Liquidity: Algorae Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 37.48% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Algorae Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Algorae Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Samsung Biologics Co Ltd
KO:207940
Biotechnology 15.21%
Abivax SA
PA:ABVX
Biotechnology 2.58%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Sinocelltech Group Ltd
SHG:688520
Biotechnology 5.27%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 1.75%
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS
Biotechnology 78.33%
GH Research PLC
NASDAQ:GHRS
Biotechnology 4.73%

Algorae Pharmaceuticals Ltd Asset Resilience Ratio by Year (2016–2025)

Algorae Pharmaceuticals Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Algorae Pharmaceuticals Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 77.13% AU$1.85 Million
≈ $1.31 Million
AU$2.40 Million
≈ $1.70 Million
+35.26pp
2024-06-30 41.87% AU$2.30 Million
≈ $1.63 Million
AU$5.49 Million
≈ $3.89 Million
--
2023-06-30 0.00% AU$0.00
≈ $0.00
AU$6.23 Million
≈ $4.41 Million
--
2022-06-30 0.00% AU$0.00
≈ $0.00
AU$4.27 Million
≈ $3.02 Million
--
2021-06-30 2.64% AU$43.30K
≈ $30.64K
AU$1.64 Million
≈ $1.16 Million
-86.07pp
2020-06-30 88.71% AU$3.01 Million
≈ $2.13 Million
AU$3.39 Million
≈ $2.40 Million
+3.50pp
2019-06-30 85.21% AU$4.91 Million
≈ $3.47 Million
AU$5.76 Million
≈ $4.08 Million
-4.97pp
2018-06-30 90.18% AU$6.86 Million
≈ $4.86 Million
AU$7.61 Million
≈ $5.38 Million
+3.57pp
2017-06-30 86.61% AU$7.53 Million
≈ $5.33 Million
AU$8.69 Million
≈ $6.15 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$6.31 Million
≈ $4.47 Million
--
pp = percentage points

About Algorae Pharmaceuticals Ltd

AU:1AI Australia Biotechnology
Market Cap
$12.88 Million
AU$18.21 Million AUD
Market Cap Rank
#26248 Global
#1169 in Australia
Share Price
AU$0.01
Change (1 day)
+0.00%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$0.25
About

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more